Mortality Associated With Opioid Overdose: A Review of Clinical Characteristics and Health Services Received in the Year Prior to Death.


Journal

Psychiatric services (Washington, D.C.)
ISSN: 1557-9700
Titre abrégé: Psychiatr Serv
Pays: United States
ID NLM: 9502838

Informations de publication

Date de publication:
01 02 2019
Historique:
pubmed: 26 10 2018
medline: 9 4 2020
entrez: 25 10 2018
Statut: ppublish

Résumé

To assess missed opportunities for reducing fatal opioid overdoses, characteristics of decedents by opioid overdose with and without problematic opioid use who received health care services within one year of death were examined. Of 157 decedents in the Worcester, Massachusetts, area between 2008 and 2012, 112 had contact with the health care system. Electronic medical records were reviewed for clinical characteristics, health service use, universal precautions, and substance use disorder management. Problematic opioid use was defined as individuals having documented opioid use disorders or aberrant drug-related behavior. Data were analyzed with chi-square tests with adjusted residual for categorical variables and t tests for continuous variables. Decedents were predominantly Caucasian males with a mean±SD age of 41.0±11.7. Problematic opioid use by definition meant users (N=53) had opioid use disorder as a principal diagnosis and were likely to have a comorbid substance use disorder. Decedents with nonproblematic opioid use had diagnoses of chronic pain and mental illness. They were more likely to have been seen last in surgical and subspecialty settings (29% versus 11%). The proportion with an opioid prescription was higher among those with problematic use (72% versus 37%) who also had a higher total daily morphine equivalent, compared with those with nonproblematic use (165.4±282.7 versus 55.6±117.7 mg per day). Persons with problematic opioid use are a recognizable group with a high risk of death by opioid overdose whose therapeutic management needs improvement to reduce fatal outcomes. Different strategies must be developed for identifying and treating nonproblematic opioid use to reduce risk of death.

Identifiants

pubmed: 30353791
doi: 10.1176/appi.ps.201800122
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-96

Commentaires et corrections

Type : CommentIn

Auteurs

Christian Rose (C)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Abtin Shahanaghi (A)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Mauricio Romero-Gonzalez (M)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Jorge Yarzebski (J)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Michael Andre (M)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Gregory J DiGirolamo (GJ)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Alan P Brown (AP)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Gerardo Gonzalez (G)

Division of Addiction Psychiatry, Department of Psychiatry (all but Yarzebski), Department of Quantitative Health Sciences (Yarzebski), and Department of Radiology (DiGirolamo), University of Massachusetts Medical School, Worcester; Department of Family Medicine (Rose) and Department of Psychiatry (Shahanaghi), Boston Medical Center, Boston; MAYU of New England, New Haven, Connecticut (Romero-Gonzalez); Department of Psychology, College of the Holy Cross, Worcester (DiGirolamo); U.S. Department of Veterans Affairs Central Western Massachusetts Healthcare System, Leeds (Gonzalez).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH